Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTXNASDAQ:ONCNASDAQ:RVMDNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$98.76+0.5%$102.79$76.53▼$131.49$23.70B1.07858,489 shs723,188 shsONCBeigene$230.98+1.2%$245.97$126.97▼$287.88$22.79B0.49491,582 shs519,865 shsRVMDRevolution Medicines$36.76+1.5%$37.88$29.17▼$62.40$6.83B1.371.42 million shs1.27 million shsSMMTSummit Therapeutics$24.61+6.8%$20.02$2.10▼$33.89$18.15B-0.463.59 million shs3.45 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+0.52%+6.06%-0.20%-11.77%+14.31%ONCBeigene+1.24%+10.88%-11.63%+23,097,999,900.00%+23,097,999,900.00%RVMDRevolution Medicines+1.55%+9.18%-3.67%-8.76%-0.16%SMMTSummit Therapeutics+6.77%+22.13%+24.10%+29.32%+589.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.4116 of 5 stars4.42.00.00.02.40.80.0ONCBeigene2.1353 of 5 stars3.50.00.00.02.31.70.6RVMDRevolution Medicines3.7146 of 5 stars3.51.00.04.72.82.50.0SMMTSummit Therapeutics2.8078 of 5 stars4.51.00.00.03.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.89Moderate Buy$143.4445.24% UpsideONCBeigene 3.00Buy$316.6737.10% UpsideRVMDRevolution Medicines 3.00Buy$66.6781.36% UpsideSMMTSummit Therapeutics 3.00Buy$35.4043.84% UpsideCurrent Analyst Ratings BreakdownLatest RVMD, BNTX, ONC, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.004/1/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/26/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$35.003/26/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$23.00 ➝ $35.003/21/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/13/2025ONCBeigeneSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$259.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.75B8.61$4.25 per share23.25$92.17 per share1.07ONCBeigene$3.81B5.98N/AN/A$37.10 per share6.23RVMDRevolution Medicines$742K9,210.46N/AN/A$11.09 per share3.31SMMTSummit Therapeutics$700K25,934.72N/AN/A$0.11 per share223.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)ONCBeigene-$881.71M-$6.14N/A325.327.73-25.94%-25.12%-14.95%N/ARVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/6/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%4/29/2025 (Estimated)Latest RVMD, BNTX, ONC, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/5/2025Q1 2025BNTXBioNTech-$2.68N/AN/AN/AN/AN/A4/29/2025Q1 2025SMMTSummit Therapeutics-$0.0715N/AN/AN/AN/AN/A3/10/2025Q4 2024BNTXBioNTech$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion2/27/2025Q4 2024ONCBeigene-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billion2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.55%N/AN/A N/AONCBeigeneN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.017.337.21ONCBeigene0.051.931.72RVMDRevolution MedicinesN/A14.2414.24SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%ONCBeigene48.55%RVMDRevolution Medicines94.34%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%ONCBeigene7.43%RVMDRevolution Medicines8.00%SMMTSummit Therapeutics88.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech3,080239.97 million193.71 millionOptionableONCBeigene9,00098.69 million90.59 millionN/ARVMDRevolution Medicines250185.91 million154.76 millionOptionableSMMTSummit Therapeutics110737.68 million86.28 millionOptionableRVMD, BNTX, ONC, and SMMT HeadlinesRecent News About These CompaniesWhy Summit Therapeutics Inc.’s (SMMT) Stock Is Up 5.60%April 18 at 6:33 AM | aaii.comAnalysts Set Summit Therapeutics Inc. (NASDAQ:SMMT) Price Target at $35.40April 18 at 1:29 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4% - Time to Sell?April 17 at 1:46 PM | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Given Consensus Recommendation of "Buy" by BrokeragesApril 16 at 4:09 AM | marketbeat.comFmr LLC Cuts Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)April 15 at 3:58 AM | marketbeat.comFranklin Resources Inc. Purchases 57,803 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)April 15 at 3:57 AM | marketbeat.comGeode Capital Management LLC Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)April 15 at 3:39 AM | marketbeat.comAmerican Century Companies Inc. Invests $231,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)April 15 at 3:07 AM | marketbeat.comWhy Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday?April 15 at 2:14 AM | insidermonkey.comNorges Bank Invests $1.78 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)April 14, 2025 | marketbeat.comWhy Summit Therapeutics Inc. (SMMT) Soared Last Week?April 12, 2025 | insidermonkey.comWhy Summit Therapeutics Inc. (SMMT) Soared Last Week?April 12, 2025 | finance.yahoo.com3 Magnificent Stocks That Could Double or More by 2030April 12, 2025 | fool.comWhy Summit Therapeutics Inc. (SMMT) Went Up On Thursday?April 12, 2025 | finance.yahoo.comWhy Summit Therapeutics Inc. (SMMT) Surged On Friday?April 12, 2025 | msn.comWhy Summit Therapeutics Inc. (SMMT) Went Up On Thursday?April 11, 2025 | insidermonkey.comInvestors Purchase Large Volume of Summit Therapeutics Call Options (NASDAQ:SMMT)April 11, 2025 | americanbankingnews.comSummit co-CEO option exercise ‘quite bullish,’ says Cantor FitzgeraldApril 11, 2025 | markets.businessinsider.comSummit Therapeutics (SMMT) Gets a Buy from Truist FinancialApril 11, 2025 | markets.businessinsider.comWhy Summit Therapeutics Rallied Double Digits Today on Another Down day for the MarketsApril 10, 2025 | fool.comPolymer Capital Management HK LTD Invests $3.92 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)April 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Flying Under the Radar—But Not for LongBy Nathan Reiff | March 20, 2025View 3 Semiconductor Stocks Flying Under the Radar—But Not for LongViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsMarvell Gets Tariff Lifeline But Expect More VolatilityBy Chris Markoch | April 11, 2025View Marvell Gets Tariff Lifeline But Expect More Volatility 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsBy MarketBeat Staff | April 5, 2025View Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsRVMD, BNTX, ONC, and SMMT Company DescriptionsBioNTech NASDAQ:BNTX$98.76 +0.51 (+0.52%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$98.77 +0.01 (+0.01%) As of 04/17/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Beigene NASDAQ:ONC$230.98 +2.84 (+1.24%) As of 04/17/2025 04:00 PM EasternBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Revolution Medicines NASDAQ:RVMD$36.76 +0.56 (+1.55%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$36.78 +0.02 (+0.04%) As of 04/17/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Summit Therapeutics NASDAQ:SMMT$24.61 +1.56 (+6.77%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$24.70 +0.09 (+0.39%) As of 04/17/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
